Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on

Cancers, Free Full-Text

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy

177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration

Figure 5 from Lu-177-PSMA-617 Prostate-Specific Membrane Antigen

Lu-177 PSMA therapy in Germany

Optimizing treatment activities for [ 225 Ac]Ac-and [ 177 Lu]Lu

Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including

Lutetium-177 prostate-specific membrane antigen (PSMA

EAU 2022: Discussion: LuTectomy – A Single-arm Study of the

PDF) Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA

Lutetium-177 prostate-specific membrane antigen (PSMA

CUB domain containing protein 1 (CDPC1) is a target for

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on

Frontiers 177Lu-labeled PSMA targeting therapeutic with